| Authors: |
Turpin A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Delliaux C; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Parent P; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Chevalier H; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Escudero-Iriarte C; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Bonardi F; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000, Lille, France., Vanpouille N; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Flourens A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Querol J; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Carnot A; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Leroy X; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Herranz N; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Lanel T; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Villers A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Olivier J; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Touzet H; University Lille, CNRS, Centrale Lille, UMR 9189 CRIStAL, F-59000, Lille, France., de Launoit Y; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Tian TV; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Duterque-Coquillaud M; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. martine.duterque@cnrs.fr. |
